Voriconazole

Generic Name: Voriconazole

Brand Names: Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄F_₃N_₅O

CAS Number: 137234-62-9

Unique Ingredient Identifier: JFU09I87TR

Background: Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...

Indication: For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

Associated Conditions: Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis

Associated Therapies: -

Clinical Trials

Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Voriconazole

First Posted Date: 2009-07-21

Last Posted Date: 2010-03-04

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 18

Registration Number: NCT00942773

Locations: 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

Phase 3

Completed

Conditions: Leukemia
Fungal Infection

Interventions: Drug: Voriconazole

First Posted Date: 2009-05-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00904995

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Pharmacologic Optimization of Voriconazole

Phase 3

Completed

Conditions: Invasive Fungal Infection
Hematological Malignancy

Interventions: Drug: voriconazole (dosing according to the SPC)
Drug: voriconazole

First Posted Date: 2009-05-06

Last Posted Date: 2017-01-12

Lead Sponsor: Jan-Willem C Alffenaar

Target Recruit Count: 189

Registration Number: NCT00893555

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: voriconazole

First Posted Date: 2009-03-04

Last Posted Date: 2010-06-14

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00855101

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Phase 3

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Voriconazole

First Posted Date: 2009-02-04

Last Posted Date: 2017-06-16

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT00836875

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇹🇭
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Patumwan, Bangkok, Thailand
🇹🇭
Department of Pediatrics, Phramongkutklao hospital, Rajathevee, Bangkok, Thailand

and more 21 locations